Mark Foley - Glaukos Corp Lead Independent Director
| GKOS Stock | USD 100.63 0.61 0.60% |
Director
Mr. Mark J. Foley serves as an Independent Director of the Company. Mr. Foley was the chairman, president and chief executive officer of ZELTIQ Aesthetics, Inc., a medical technology company, prior to its acquisition by Allergan plc in April 2017. Prior to becoming ZELTIQs chief executive officer in 2012, Mr. Foley served on its board of directors and held the position of executive chairman from July 2009 to May 2010. Mr. Foley also served as executive chairman at Onpharma Inc. from August 2009 until its acquisition by Valeant Pharmaceuticals International, Inc. in March 2014. Mr. Foley has served as a managing director at RWI Ventures, Inc. since 2004, where he focuses on healthcare investments. Prior to this, Mr. Foley held a variety of operating roles in large, public companies and venturebacked startups including United States Surgical Corporationrationration, Guidant Corporationrationration, Devices for Vascular Intervention, Inc., Perclose, Inc. and Ventrica, Inc. where he was the founder and chief executive officer. Mr. Foley has over 25 years of medical device operating, investment and chief executive officer experience. Mr. Foley currently serves as the chairman of the audit committee for Revance Therapeutics, Inc. since 2021.
| Age | 55 |
| Tenure | 4 years |
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Mark Foley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Foley against Glaukos Corp stock is an integral part of due diligence when investing in Glaukos Corp. Mark Foley insider activity provides valuable insight into whether Glaukos Corp is net buyers or sellers over its current business cycle. Note, Glaukos Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Glaukos Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Foley over two weeks ago Disposition of 15000 shares by Mark Foley of Glaukos Corp at 24.69 subject to Rule 16b-3 | ||
Mark Foley over two months ago Acquisition by Mark Foley of 1000 shares of Revance at 2.1845 subject to Rule 16b-3 | ||
Mark Foley over six months ago Acquisition by Mark Foley of 1246 shares of Glaukos Corp at 110.7 subject to Rule 16b-3 | ||
Mark Foley over a year ago Disposition of 17228 shares by Mark Foley of Revance at 5.305 subject to Rule 16b-3 |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0706) % which means that it has lost $0.0706 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2383) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2025. Return On Capital Employed is likely to drop to -0.14 in 2025. At this time, Glaukos Corp's Non Currrent Assets Other are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 640 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 287.1 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael DeMane | Nevro Corp | 63 | |
| Martha Aronson | CONMED | 53 | |
| Kristen CFA | Integer Holdings Corp | N/A | |
| Brian Concannon | CONMED | 62 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Fred Hite | Orthopediatrics Corp | 57 | |
| Shawn McCormick | Nevro Corp | 56 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Susan Siegel | Nevro Corp | 60 | |
| David Bronson | CONMED | 67 | |
| Brad Vale | Nevro Corp | 67 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Elizabeth Weatherman | Nevro Corp | 60 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Jerome Lande | CONMED | 45 | |
| William Summers | Integer Holdings Corp | 70 | |
| Filippo Passerini | Integer Holdings Corp | 63 | |
| Charles Farkas | CONMED | 68 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Joel Suiter | SurModics | N/A | |
Management Performance
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0706 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilbert Kliman, Independent Director | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Diane Biagianti, Sr Counsel | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Aimee Weisner, Independent Director | ||
| Mory Gharib, CoFounder | ||
| Michele Allegretto, Senior Resources | ||
| Robert Davis, General VP | ||
| David Hoffmeister, Independent Director | ||
| Denice Torres, Independent Director | ||
| Tracy Founds, Senior Safety | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0706 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 5.51 B | ||||
| Shares Outstanding | 56.57 M | ||||
| Shares Owned By Insiders | 3.16 % | ||||
| Shares Owned By Institutions | 96.84 % | ||||
| Number Of Shares Shorted | 3.54 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.